Drug candidates with the goal of launching or out-licensing drugs for the treatment of Diffuse large B-cell lymphoma (cancer)

Svenska investerarsidor

Collaborations with strategic partners

who assume the financial and operational responsibility for developing an approved product.

BUSINESS CONCEPT

Drug candidates based on patent-pending substances that have shown superior results in preclinical studies.

STRATEGY

To add knowledge and resources from global partners at an early stage in the value chain to minimize the time to product launch.

VISION

Reduce the global burden of aggressive lymphoma (cancer).

Respiratorius Project Portfolio

VAL001 has shown clearly promising experimental and clinical data against diseases such as diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin’s lymphoma.

The Company has successfully completed a phase I/IIa study that was conducted at Skåne University Hospital in Lund, Uppsala University Hospital, and Norrland University Hospital in Umeå.

VAL001 – DRUG CANDIDATEDiffuse large B-cell lymphoma (cancer)

Board of Directors and CEO

A competent team with extensive experience in both business development and commercialization of research findings as well as strong scientific background in relevant areas complemented with knowledge in clinical development and design of clinical trials.

Niklas Prager

Chairman of the Board

Niklas Prager has an MBA from Handelshögskolan (the Stockholm School of Economics) and has since gained extensive experience in company management, board work and investment. Niklas Prager’s career has included CEO of the Swedish division of pharmaceutical company Pfizer and several other CEO positions, including CEO of Medivir AB.

Peter Buhl Jensen

Board Member

Peter Buhl Jensen has an MD and DMSc from the University of Copenhagen. Peter Buhl Jensen has a strong combination of commercial and medical experience, primarily in the development of cancer drugs. As a serial entrepreneur with broad experience in the life science sector, Peter is the founder of TopoTarget, Oncology Venture, Medical Prognosis Institute and several other successful companies.

Johan Drott

CEO

Johan has an extensive experience in senior positions in medical device and pharmaceutical companies with a focus on research, business development and commercialization of research findings.

Kristina Drott

Board member

Kristina is associate professor at the Faculty of Medicine, Lund University and senior consultant of lymphoma oncology at Skåne University Hospital.

Anna Törner